How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?;Cómo pueden contribuir los sistemas de remuneraciónfarmacéutica a la dispensación de medicamentos gené

Pharmacy Practice

Volumn 10, Issue 1, 2012, Pages 3-8

  Dylst, Pieter ^a   Vulto, Arnold ^b   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Drug substitution; Drugs, generic; Europe; Fees, pharmaceutical; Pharmacists

Indexed keywords

GENERIC DRUG;

BELGIUM; DRUG COST; DRUG MARKETING; EUROPE; FRANCE; HUMAN; MEDICAL SOCIETY; NETHERLANDS; PHARMACIST; REMUNERATION; REVIEW; UNITED KINGDOM;

EID: 84858713526     PISSN: None     EISSN: 18863655     Source Type: Journal    
DOI: 10.4321/S1886-36552012000100002     Document Type: Review

References (21)

1. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, Garuolienè K, Kalaba M, Laius O, Joppi R, Sermet C, Schwabe U, Teixeira IF. Tulunay C, Wendykowska K, Zara C, Gustafsson LL. Use of generics-A critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470-2494.
2. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. Leuven, Belgium: K U Leuven; 2006. Available at: www.egagenerics.com [Last accessed: 15 November 2011]
3. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on The Community code relating to medicinal products for human use. Official Journal of the European Union L 136/34-57, European Commission, (2004).
4. European Generic Medicines Association. 2011 Market Review. Brussels, Belgium: European Generic Medicines Association; 2011.
5. Carpentier P, Louwies L, Otten P, Van Cakenbergh A, Van Laethem L, Verbruggen K. Research on pricing strategies and discounts on generic drugs and the impact of the new remuneration system for pharmacists in Belgium. Leuven, Belgium: K.U.Leuven; 2011.
6. RIZIV/INAMI. Overall analysis report on the content of Farmanet-unique track. Brussels, Belgium: RIZIV/INAMI; 2009.
7. Macarthur D. European pharmaceutical distribution: Key players, challenges and future strategies. London, United Kingdom: SCRIP Reports; 2007. Report No.: BS1353. Available at: http://www.scripintelligence.com/multimedia/archive/00000/BS1353_124a.pdf [Last accessed: 18 November 2011]
8. Nederlandse Zorgauthoriteit (NZa). Purchasing advantages and practice costs for pharmacies 2009, 2010 and 2011. Utrecht, the Netherlands: Nederlandse Zorgauthoriteit; 2010. Available at: http://www.farmaactueel.nl/beleidsstukken/rapport-inkoopvoordelen-apotheekhoudenden-2009.pdf [Last accessed 18 November 2011]
9. Stichting Farmaceutische Kengetallen. Facts and figures 2011: 2010 in numbers. Stichting Farmaceutische Kengetallen; 2011. Available at: http://www.sfk.nl/publicaties/data_en_feiten.html [Last accessed: 18 November 2011]
10. Office of Fair Trading. Medicines distribution: an OFT market study. London, United Kingdom: Office of Fair Trading; 2007. Available at: http://www.sfk.nl/publicaties/data_en_feiten.html [Last accessed: 21 November 2011].
11. Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin. 2007;23(1):105-116.
12. Pharmaceutical Pricing and Reimbursement Information. France: pharma profile. Vienna, Austria: PPRI; 2008. Available at: http://whocc.goeg.at/ [Last accessed: 18 November 2011]
13. Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr Med Res Opin. 2007;23(10):2467-2476.
14. European Generic Medicines Association. How to increase patient access to generic medicines in European healthcare systems. Brussels, Belgium: European Generic Medicines Association; 2009. Available at: www.egagenerics.com [Last accessed: 16 November 2011]
15. Schwermann T, Greiner W, v.d.Schulenberg G. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value Health. 2003;6(1):20-30.
16. Silversides A. Pharmacies receiving massive rebates from generic drug-makers. CMAJ. 2006;175(4):342-343.
17. Bernsten C, Andersson K, Gariepy Y, Simoens S. A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy. 2010;95:1-9.
18. Simoens S. Generic medicine pricing in Europe: current issues and future perspective. J Med Econ. 2008;11:171-5.
19. IHS Global Insight. National audit office finds further room for generic-associated savings in Norway. Lexington, Massachuchets: IHS Global Insight; 2011. Available at: http://www.ihsglobalinsight.com/SDA/SDADetail16273.htm [Last accessed: 17 November 2011]
20. Simoens S. Developing competitive and sustainable Polish generic medicines market. Croat Med J. 2009;50:440-448.
21. Boonen L, van der Geest S, Schut F, Varkevisser M. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition. Adv Health Econ Health Serv Res. 2010;22:53-76.